Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352668 | 0.93 | TSHR (0.65) | TSHRLTA4HTHRBSMPD1PLA2G4B | |
| SCHEMBL26635331 | 0.93 | TSHR (0.65) | TSHRLTA4HTHRBSMPD1PLA2G4B | |
| SCHEMBL25169961 | 0.93 | TSHR (0.65) | TSHRLTA4HTHRBSMPD1PLA2G4B | |
| SCHEMBL25167623 | 0.93 | TSHR (0.65) | TSHRLTA4HTHRBSMPD1PLA2G4B | |
| SCHEMBL8552100 | 0.90 | KMT2A (0.59) | TSHRSMPD1KMT2ANR1H4SMN1; SMN2 | |
| SCHEMBL4397448 | 0.86 | TSHR (0.63) | TSHRLTA4HTHRBSMPD1PLA2G4B | |
| SCHEMBL13846053 | 0.83 | CYP1A2 (0.53) | TSHRSMPD1CYP1A2CYP2C19 | |
| SCHEMBL10048853 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL22296966 | 0.82 | KCNA3 (0.64) | LTA4H | |
| 1-Butyloxy-3-Propoxybenzene SCHEMBL3390925 | 0.82 | TSHR (0.59) | TSHRLTA4HTHRBPLA2G4BTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| US-20250353867-A1 | Substituted Pyridine-2,6-Bis(Phenylenephenolate) Complexes with Enhanced Solubility that are Useful as Catalyst Components for Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-4519332-A1 | SUBSTITUTED PYRIDINE-2,6-BIS (PHENYLENEPHENOLATE) COMPLEXES WITH ENHANCED SOLUBILITY THAT ARE USEFUL AS CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024052550-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335462-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4308551-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023215695-A1 | SUBSTITUTED PYRIDINE-2,6-BIS (PHENYLENEPHENOLATE) COMPLEXES WITH ENHANCED SOLUBILITY THAT ARE USEFUL AS CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2012040204-A2 | CYTOSOLIC FLUORESCENT ION INDICATORS | ASANTE RESEARCH, LLC (US) | 2012-03-29 | — | — | WO | disclosed |
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928127-B2 | Inhibitors of matrix metallaproteinases | NOTRE DAME UNIVERSITY (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2009129036-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7521581-B2 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1707263-B1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | TOSOH CORP (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | MAG, GBA1, GLRX3 | TSHR 1914/4885LTA4H 3379/4885THRB 3574/4885 |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | TSHR 4135/4885LTA4H 504/4885THRB 3978/4885 |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | TSHR 637/4885LTA4H 3489/4885THRB 993/4885 |
| US-20250353867-A1 | Substituted Pyridine-2,6-Bis(Phenylenephenolate) Complexes with Enhanced Solubility that are Useful as Catalyst Components for Olefin Polymerization | HPD, YAP1, PAH | TSHR 4771/4885LTA4H 1957/4885THRB 4477/4885 |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | TSHR 4586/4885LTA4H 229/4885THRB 4555/4885 |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | TSHR 87/4885LTA4H 2444/4885THRB 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.